Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04722991 · ClinicalTrials.gov registry record · Phase 2
Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT04722991 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 109 participants.
The verdict
NCT04722991, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography for central assessment of the diabetic retinopathy severity score, or DRSS. Two-step DRSS improvement at 24 weeks of treatment will be the primary efficacy endpoint. DRSS assessments are repeated after completion of 48 weeks of treatment. In addition, vision threatening complications will be recorded throughout the study and assessed as secondary efficacy endpoint.
Interventions
- OTHER Placebo
- DRUG Runcaciguat (BAY1101042)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2024-04-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04722991
The ClinicalTrials.gov registry entry for NCT04722991 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04722991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04722991 about?
NCT04722991 is a clinical study titled "Non-proliferative Diabetic Retinopathy Treated With Runcaciguat". This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography for central assessment of the diabetic retinopathy severity score, or DR...
What is the current status of trial NCT04722991?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2021-03-17. Estimated completion is 2024-04-22.
What interventions are being tested in trial NCT04722991?
The interventions under investigation include: Placebo (OTHER), Runcaciguat (BAY1101042) (DRUG).
Who is sponsoring clinical trial NCT04722991?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.